Citi Downgrades Pharmaceutical Product Development (PPDI) to Hold
Tweet
Share
E-mailGet Alerts PPDI Hot Sheet
Price: $33.24 --0%
Rating Summary:
1 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 7 | New: 6
Rating Summary:
1 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 7 | New: 6
Join SI Premium – FREE
Citi downgraded Pharmaceutical Product Development (NASDAQ: PPDI) from Buy to Hold, price target cut from $38 to $33.25.
For more ratings news on Pharmaceutical Product Development click here and for the rating history of Pharmaceutical Product Development click here.
Shares of Pharmaceutical Product Development closed at $32.28 yesterday.
For more ratings news on Pharmaceutical Product Development click here and for the rating history of Pharmaceutical Product Development click here.
Shares of Pharmaceutical Product Development closed at $32.28 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Citi downgrades Ryder Systems to neutral, raises price target
- Morgan Stanley Downgrades China Yongda Automotive Services Holdings Ltd (3669:HK) (CYYHF) to Underweight
- Berenberg Downgrades Siemens Healthineers (SHL:GR) (SEMHF) to Hold
Create E-mail Alert Related Categories
DowngradesRelated Entities
CitiSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
